Segev Barak

Prof. Segev Barak

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in Alcohol
Verified
Journal Article
Closed access
SCSebastien Carnicella
Sebastien Carnicella
DRDorit Ron
Dorit Ron
SBSegev Barak
Segev Barak

19 February 2013 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
VWV Warnault
V Warnault
EDE Darcq
E Darcq
ALA Levine
A Levine
SBSegev Barak
Segev Barak
DRD Ron
D Ron
Harmful excessive use of alcohol has a severe impact on society and it remains one of the major causes of morbidity and mortality in the population. However, mechanisms that underlie excessive alcohol consumption are still poorly understood, and thus available medications for alcohol use disorders are limited. Here, we report that changing the level of chromatin condensation by affecting DNA methylation or histone acetylation limits excessive alcohol drinking and seeking behaviors in rodents. Specifically, we show that decreasing DNA methylation by inhibiting the activity of DNA methyltransferase (DNMT) with systemic administration of the FDA-approved drug, 5-azacitidine (5-AzaC) prevents excessive alcohol use in mice. Similarly, we find that increasing histone acetylation via systemic treatment with several histone deacetylase (HDAC) inhibitors reduces mice binge-like alcohol drinking. We further report that systemic administration of the FDA-approved HDAC inhibitor, SAHA, inhibits the motivation of rats to seek alcohol. Importantly, the actions of both DNMT and HDAC inhibitors are specific for alcohol, as no changes in saccharin or sucrose intake were observed. In line with these behavioral findings, we demonstrate that excessive alcohol drinking increases DNMT1 levels and reduces histone H4 acetylation in the nucleus accumbens (NAc) of rodents. Together, our findings illustrate that DNA methylation and histone acetylation control the level of excessive alcohol drinking and seeking behaviors in preclinical rodent models. Our study therefore highlights the possibility that DNMT and HDAC inhibitors can be used to treat harmful alcohol abuse.

23 June 2013 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
SBSegev Barak
Segev Barak
FLFeng Liu
Feng Liu
SHSami Ben Hamida
Sami Ben Hamida
QYQuinn V Yowell
Quinn V Yowell
JNJérémie Neasta
Jérémie Neasta
DRDorit Ron
Dorit Ron
The authors show that reconsolidation of alcohol-related memories activates mammalian target of rapamycin complex 1 (mTORC1) in select amygdalar and cortical regions and systemic or central amygdalar inhibition of mTORC1 during reconsolidation disrupts alcohol-associated memories, leading to a long-lasting suppression of relapse, suggesting a potential therapeutic target to prevent relapse. Relapse to alcohol abuse is an important clinical issue that is frequently caused by cue-induced drug craving. Therefore, disruption of the memory for the cue-alcohol association is expected to prevent relapse. It is increasingly accepted that memories become labile and erasable soon after their reactivation through retrieval during a memory reconsolidation process that depends on protein synthesis. Here we show that reconsolidation of alcohol-related memories triggered by the sensory properties of alcohol itself (odor and taste) activates mammalian target of rapamycin complex 1 (mTORC1) in select amygdalar and cortical regions in rats, resulting in increased levels of several synaptic proteins. Furthermore, systemic or central amygdalar inhibition of mTORC1 during reconsolidation disrupts alcohol-associated memories, leading to a long-lasting suppression of relapse. Our findings provide evidence that the mTORC1 pathway and its downstream substrates are crucial in alcohol-related memory reconsolidation and highlight this pathway as a therapeutic target to prevent relapse.

6 July 2011 in Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
SBSegev Barak
Segev Barak
SCSebastien Carnicella
Sebastien Carnicella
QYQuinn V. Yowell
Quinn V. Yowell
DRDorit Ron
Dorit Ron
We previously showed that infusion of glial cell line-derived neurotrophic factor (GDNF) into the ventral tegmental area (VTA) rapidly reduces alcohol intake and relapse (Carnicella et al., 2008, 2009a), and increases dopamine (DA) levels in the nucleus accumbens (NAc) of alcohol-naive rats (Wang et al., 2010). Withdrawal from excessive alcohol intake is associated with a reduction in NAc DA levels, whereas drug-induced increases in NAc DA levels are associated with reward. We therefore tested whether GDNF in the VTA reverses alcohol withdrawal-associated DA deficiency and/or possesses rewarding properties. Rats were trained for 7 weeks to consume high levels of alcohol (5.47 ± 0.37 g/kg/24 h) in intermittent access to 20% alcohol in a two-bottle choice procedure. Using in vivo microdialysis, we show that 24 h withdrawal from alcohol causes a substantial reduction in NAc DA overflow, which was reversed by intra-VTA GDNF infusion. Using conditioned place preference (CPP) paradigm, we observed that GDNF on its own does not induce CPP, suggesting that the growth factor is not rewarding. However, GDNF blocked acquisition and expression of alcohol-CPP. In addition, GDNF induced a downward shift in the dose–response curve for operant self-administration of alcohol, further suggesting that GDNF suppresses, rather than substitutes for, the reinforcing effects of alcohol. Our findings suggest that GDNF reduces alcohol-drinking behaviors by reversing an alcohol-induced allostatic DA deficiency in the mesolimbic system. In addition, as it lacks abuse liability, the study further highlights GDNF as a promising target for treatment of alcohol use/abuse disorders.

16 August 2008 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
MBMark D. Black
Mark D. Black
GVGeoffrey B. Varty
Geoffrey B. Varty
MAMichal Arad
Michal Arad
SBSegev Barak
Segev Barak
ALAmaya De Levie
Amaya De Levie
IWIna Weiner
Ina Weiner

1 October 2011 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
SBSegev Barak
Segev Barak
IWIna Weiner
Ina Weiner
A major challenge in developing schizophrenia pharmacotherapy is treating the different symptoms of this disorder, typically divided into positive, ne